In:
Immunotherapy, Future Medicine Ltd, Vol. 14, No. 18 ( 2022-12), p. 1481-1496
Abstract:
Plain language summary Immune checkpoint inhibitors (ICIs) have substantially improved the prognosis of many patients with advanced cancer. However, some patients still do not benefit from ICIs. Therefore, determining indicators that can identify patients who may benefit from ICIs is essential. As a noninvasive, convenient and inexpensive clinical indicator, the systemic immune–inflammation index is expected to solve the aforementioned issue. Through this meta-analysis, the authors demonstrated that patients with cancers with high systemic immune–inflammation index levels had shorter survival and a smaller degree of clinical benefit after ICI treatment. Moreover, a systemic immune–inflammation index value of 750 is recommended to be the cut-off value for stratifying patients.
Type of Medium:
Online Resource
ISSN:
1750-743X
,
1750-7448
DOI:
10.2217/imt-2022-0133
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2022